Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab after surgery for chronic rhinosinusitis with nasal polyps and asthma
ChiCTR2100047069Phase 4Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of omalizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Count of eosinophils in nasal polyp tissue. Started Sep 2021; status: recruiting.
02
Drugs
omalizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)asthma
Beyond the preview
Go deeper on ChiCTR2100047069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047069.